HC Wainwright Has Positive Opinion of TARA FY2026 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for Protara Therapeutics in a research note issued to investors on Monday, November 9th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.35) for the year, up from their previous forecast of ($1.38). The consensus estimate for Protara Therapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q4 2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.34) EPS, FY2027 earnings at ($1.37) EPS and FY2028 earnings at ($0.41) EPS.

Several other equities research analysts also recently weighed in on TARA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Protara Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $26.25.

Protara Therapeutics Stock Down 3.2%

Shares of Protara Therapeutics stock opened at $2.43 on Wednesday. Protara Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.82. The company has a fifty day moving average price of $2.97 and a 200 day moving average price of $4.46.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TARA. Fisher Asset Management LLC boosted its holdings in Protara Therapeutics by 30.2% in the third quarter. Fisher Asset Management LLC now owns 129,612 shares of the company’s stock worth $395,000 after purchasing an additional 30,046 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Protara Therapeutics by 36.3% in the 3rd quarter. Alps Advisors Inc. now owns 77,735 shares of the company’s stock valued at $237,000 after buying an additional 20,694 shares during the period. WINTON GROUP Ltd boosted its holdings in shares of Protara Therapeutics by 16.7% in the 2nd quarter. WINTON GROUP Ltd now owns 32,800 shares of the company’s stock valued at $125,000 after buying an additional 4,700 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Protara Therapeutics during the 2nd quarter valued at about $69,000. Finally, Corient Private Wealth LP bought a new stake in shares of Protara Therapeutics during the 2nd quarter valued at about $41,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer. Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.